Closed-loop insulin delivery for treatment of type 1 diabetes

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Elleri, Daniela ^a   Dunger, David B ^a   Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; DRUG DELIVERY SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; REVIEW; ADOLESCENT; ADULT; CHILD; INSULIN INFUSION;

ADOLESCENT; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN INFUSION SYSTEMS; PANCREAS, ARTIFICIAL;

EID: 80655141686     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-120     Document Type: Review

References (64)

1. Todd JA. Etiology of type 1 diabetes. Immunity 2010, 32:457-467. 10.1016/j.immuni.2010.04.001, 20412756.
2. Diabetes Control and Complication Trial Study Group (DCCT) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes-mellitus. N Engl J Med 1993, 329:977-986. Diabetes Control and Complication Trial Study Group (DCCT).
3. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008, 57:3169-3176. 10.2337/db08-1084, 2584119, 19033403.
4. Nixon R, Pickup JC. Fear of hypoglycemia in type 1 diabetes managed by continuous subcutaneous insulin infusion: is it associated with poor glycemic control?. Diabetes Technol Ther 2011, 13:93-98. 10.1089/dia.2010.0192, 21284474.
5. Wild D, Von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns 2007, 68:10-15. 10.1016/j.pec.2007.05.003, 17582726.
6. Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 2005, 28:1231-1239. 10.2337/diacare.28.5.1231, 15855600.
7. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010, 363:311-320. 10.1056/NEJMoa1002853, 20587585.
8. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008, 359:1464-1476.
9. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med 2006, 23:1-12.
10. Steil GM, Rebrin K. Closed-loop insulin delivery - what lies between where we are and where we are going?. Expert Opin Drug Deliv 2005, 2:353-362. 10.1517/17425247.2.2.353, 16296759.
11. Renard E, Costalat G, Chevassus H, Bringer J. Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab 2006, 32:497-502. 10.1016/S1262-3636(06)72802-6, 17130808.
12. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011, 7:385-395. 10.1038/nrendo.2011.32, 21343892.
13. Bequette BW. A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol Ther 2005, 7:28-47. 10.1089/dia.2005.7.28, 15738702.
14. Marchetti G, Barolo M, Jovanovic L, Zisser H, Seborg DE. An improved PID switching control strategy for type 1 diabetes. IEEE Trans Biomed Eng 2008, 55:857-865.
15. Steil GM, Panteleon AE, Rebrin K. Closed-loop insulin delivery-the path to physiological glucose control. Adv Drug Deliv Rev 2004, 56:125-144. 10.1016/j.addr.2003.08.011, 14741112.
16. Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, Orsini FM, Pieber TR, Schaller HC, Schaupp L, Vering T, Wilinska ME. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 2004, 25:905-920. 10.1088/0967-3334/25/4/010, 15382830.
17. Magni L, Raimondo DM, Bossi L, Man CD, De NG, Kovatchev B, Cobelli C. Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 2007, 1:804-812. 2769684, 19885152.
18. Parker RS, Doyle FJ, Peppas NA. A model-based algorithm for blood glucose control in type I diabetic patients. IEEE Trans Biomed Eng 1999, 46:148-157. 10.1109/10.740877, 9932336.
19. El-Khatib FH, Jiang J, Damiano ER. Adaptive closed-loop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic swine. J Diabetes Sci Technol 2007, 1:181-192. 2771467, 19888405.
20. Lee H, Buckingham BA, Wilson DM, Bequette BW. A closed-loop artificial pancreas using model predictive control and a sliding meal size estimator. J Diabetes Sci Technol 2009, 3:1082-1090. 2769914, 20144421.
21. Wang Y, Dassau E, Doyle FJ. Closed-loop control of artificial pancreatic Beta -cell in type 1 diabetes mellitus using model predictive iterative learning control. IEEE Trans Biomed Eng 2010, 57:211-219.
22. Grosman B, Dassau E, Zisser HC, Jovanovic L, Doyle FJ. Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events. J Diabetes Sci Technol 2010, 4:961-975. 2909531, 20663463.
23. Kovatchev B, Patek S, Dassau E, Doyle FJ, Magni L, De NG, Cobelli C. Control to range for diabetes: functionality and modular architecture. J Diabetes Sci Technol 2009, 3:1058-1065. 2769910, 20144419.
24. Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, Kollman C, Hovorka T, Larsen AM, Nodale M, De PA, Wilinska ME, Acerini CL, Dunger DB. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010, 375:743-751. 10.1016/S0140-6736(09)61998-X, 20138357.
25. Atlas E, Nimri R, Miller S, Grunberg EA, Phillip M. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 2010, 33:1072-1076. 10.2337/dc09-1830, 2858178, 20150292.
26. Steil GM, Palerm CC, Kurtz N, Voskanyan G, Roy A, Paz S, Kandeel FR. The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab 2011, 96:1402-1408. 10.1210/jc.2010-2578, 21367930.
27. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther 2009, 11:S113-S119. 10.1089/dia.2008.0021, 19621478.
28. Buckingham B, Wilson DM, Lecher T, Hanas R, Kaiserman K, Cameron F. Duration of nocturnal hypoglycemia before seizures. Diabetes Care 2008, 31:2110-2112. 10.2337/dc08-0863, 2571056, 18694975.
29. Cryer PE. Glucose counterregulation in normal and diabetic man. Clin Physiol 1985, 5(Suppl 5):61-65.
30. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 2005, 54:3592-3601. 10.2337/diabetes.54.12.3592, 16306382.
31. Simonson DC, Tamborlane WV, DeFronzo RA, Sherwin RS. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes. Ann. Intern Med 1985, 103:184-190.
32. Jones TW, Porter P, Sherwin RS, Davis EA, O'Leary P, Frazer F, Byrne G, Stick S, Tamborlane WV. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998, 338:1657-1662. 10.1056/NEJM199806043382303, 9614256.
33. Pickup JC. Semi-closed-loop insulin delivery systems: early experience with low-glucose insulin suspend pumps. Diabetes Technol Ther 2011, 13:695-698. 10.1089/dia.2011.0103, 21668344.
34. Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998, 21:817-821. 10.2337/diacare.21.5.817, 9589247.
35. Guerci B, Meyer L, Salle A, Charrie A, Dousset B, Ziegler O, Drouin P. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab 1999, 84:2673-2678. 10.1210/jc.84.8.2673, 10443658.
36. Krzentowski G, Scheen A, Castillo M, Luyckx AS, Lefebvre PJ. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia 1983, 24:314-318.
37. Pickup JC, Viberti GC, Bilous RW, Keen H, Alberti KGMM, Home PD, Binder C. Safety of continuous subcutaneous insulin infusion. Metabolic deterioration and glycemic auto-regulation after deliberate cessation of infusion. Diabetologia 1982, 22:175-179.
38. Scheen A, Castillo M, Jandrain B, Krzentowski G, Henrivaux P, Luyckx A, Lefebvre P. A 2-hour nocturnal interruption of continuous subcutaneous insulin infusion induces a delayed and sustained metabolic deterioration in C-peptide negative type-1 (insulin-dependent) diabetic patients. Diabetologia 1983, 25:192-192.
39. Buckingham B, Cobry E, Clinton P, Gage V, Caswell K, Kunselman E, Cameron F, Chase HP. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther 2009, 11:93-97. 10.1089/dia.2008.0032, 2979338, 19848575.
40. Buckingham B, Chase HP, Dassau E, Cobry E, Clinton P, Gage V, Caswell K, Wilkinson J, Cameron F, Lee H, Bequette BW, Doyle FJ. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care 2010, 33:1013-1017. 10.2337/dc09-2303, 2858164, 20200307.
41. Diabetes Control and Complication Trial Study Group (DCCT) Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991, 90:450-459. Diabetes Control and Complication Trial Study Group (DCCT).
42. Elleri D, Acerini CL, Allen JM, Hayes J, Pesterfield C, Wilinska ME, Dunger DB, Hovorka R. Parental attitudes towards overnight closed-loop glucose control in children with type 1 diabetes. Diabetes Technol Ther 2010, 12:35-39. 10.1089/dia.2009.0084, 20082583.
43. Hovorka R, Kumareswaran K, Harris J, Allen JM, Elleri D, Xing D, Kollman C, Nodale M, Murphy HR, Dunger DB, Amiel SA, Heller SR, Wilinska ME, Evans ML. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011, 342:d1855. 10.1136/bmj.d1855, 3077739, 21493665.
44. Murphy HR, Elleri D, Allen JM, Harris J, Simmons D, Rayman G, Temple R, Dunger DB, Haidar A, Nodale M, Wilinska ME, Hovorka R. Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 2011, 34:406-411. 10.2337/dc10-1796, 21216859.
45. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semi-automated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008, 31:934-939. 10.2337/dc07-1967, 18252903.
46. Murphy HR, Kumareswaran K, Elleri D, Allen JM, Caldwell K, Biagioni M, Simmons D, Dunger DB, Nodale M, Wilinska ME, Amiel SA, Hovorka R. Safety and efficacy of 24 h closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes: a randomized crossover case series. Diabetes Care 2011,
47. Castle JR, Engle JM, El YJ, Massoud RG, Yuen KC, Kagan R, Ward WK. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010, 33:1282-1287. 10.2337/dc09-2254, 2875438, 20332355.
48. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010, 2:27ra27. 10.1126/scitranslmed.3000619, 20393188.
49. Wilinska ME, Chassin LJ, Acerini CL, Allen JM, Dunger DB, Hovorka R. Simulation environment to evaluate closed-loop insulin delivery systems in type 1 diabetes. J Diabetes Sci Technol 2010, 4:132-144. 2825634, 20167177.
50. Kovatchev BP, Breton M, Man CD, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol 2009, 3:44-55. 2681269,2681269, 19444330.
51. Wilinska ME, Budiman ES, Taub MB, Elleri D, Allen JM, Acerini CL, Dunger DB, Hovorka R. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Technol 2009, 3:1109-1120. 2769888, 20144424.
52. Kanderian SS, Weinzimer S, Voskanyan G, Steil GM. Identification of intraday metabolic profiles during closed-loop glucose control in individuals with type 1 diabetes. J Diabetes Sci Technol 2009, 3:1047-1057. 2769900, 20144418.
53. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Satisfaction with continuous glucose monitoring in adults and youths with Type 1 diabetes. Diabet Med 2011, 28(9):1118-1122. 10.1111/j.1464-5491.2011.03368.x, 21692844, Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
54. Elleri D, Harris J, Kumareswaran K, Allen JM, Haidar A, Nodale M, Swamy A, Wilinska ME, Weston J, Acerini CL, Jackson N, Umpleby AM, Evans ML, Dunger DB, Hovorka R. Glucose appearance of large slowly-absorbed evening meal containing complex carbohydrates (CHO) in type 1 diabetes (T1D). Diabetologia 2010, 53(Suppl 1):S 272.
55. Weinzimer SA, Sherr JL, Cengiz E, Kim G, Carria L, Tamborlane WV. Effect of adjuvant injected pramlintide on closed-loop automated insulin delivery. Diabetes 2011, 60(Supll 1):A 253.
56. Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care 2011, 34:666-668. 10.2337/dc10-1892, 21273493.
57. Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T, Pfutzner A, Heinemann L. A novel insulin formulation with a more rapid onset of action. Diabetologia 2008, 51:1602-1606. 10.1007/s00125-008-1095-8, 2516197, 18641968.
58. Renard E, Place J, Cantwell M, Chevassus H, Palerm CC. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care 2010, 33:121-127. 10.2337/dc09-1080, 2797956, 19846796.
59. Liebl A, Hoogma R, Renard E, Geelhoed-Duijvestijn PH, Klein E, Diglas J, Kessler L, Melki V, Diem P, Brun JM, Schaepelynck-Belicar P, Frei T. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. Diabetes Obes Metab 2009, 11:1001-1008. 10.1111/j.1463-1326.2009.01059.x, 19740082.
60. Kumareswaran K, Elleri D, Allen JM, Harris J, Xing D, Kollman C, Nodale M, Murphy HR, Amiel SA, Heller SR, Wilinska ME, Acerini CL, Evans ML, Dunger DB, Hovorka R. Meta-analysis of overnight closed-loop randomised studies in children and adults with type 1 diabetes: the Cambridge cohort. J Diabetes Sci Technol 2011,
61. Choudhary P, Shin J, Wang Y, Evans ML, Hammond PJ, Kerr D, Shaw JA, Pickup JC, Amiel SA. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011, 34:2023-2025. 10.2337/dc10-2411, 21868778.
62. Danne T, Kordonouri O, Holder M, Haberland H, Golembowski S, Remus K, Blasig S, Wadien T, Zierow S, Hartmann R, Thomas A. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011, 13:1-6. 10.1089/dia.2010.0116, 21142975.
63. Kovatchev B, Cobelli C, Renard E, Anderson S, Breton M, Patek S, Clarke W, Bruttomesso D, Maran A, Costa S, Avogaro A, Dalla MC, Facchinetti A, Magni L, De NG, Place J, Farret A. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol 2010, 4:1374-1381. 3005047, 21129332.
64. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006, 55:3344-3350. 10.2337/db06-0419, 17130478.